Moon Capital Management Has Cut Brookfield Asset Mgmt Cl A (BAM) Holding By $30.70 Million; Orexigen Therapeutics (OREX) Shorts Down By 8.43%

Orexigen Therapeutics, Inc. (NASDAQ:OREX) Logo

Moon Capital Management Llc decreased Brookfield Asset Mgmt Cl A (BAM) stake by 0.61% reported in 2017Q4 SEC filing. Moon Capital Management Llc sold 705 shares as Brookfield Asset Mgmt Cl A (BAM)’s stock declined 9.58%. The Moon Capital Management Llc holds 114,979 shares with $5.01 billion value, down from 115,684 last quarter. Brookfield Asset Mgmt Cl A now has $36.90B valuation. The stock increased 0.59% or $0.23 during the last trading session, reaching $39. About 2.14 million shares traded or 59.28% up from the average. Brookfield Asset Management Inc. (NYSE:BAM) has risen 7.96% since March 30, 2017 and is uptrending. It has underperformed by 3.59% the S&P500.

Orexigen Therapeutics Inc (NASDAQ:OREX) had a decrease of 8.43% in short interest. OREX’s SI was 877,100 shares in March as released by FINRA. Its down 8.43% from 957,800 shares previously. With 263,300 avg volume, 3 days are for Orexigen Therapeutics Inc (NASDAQ:OREX)’s short sellers to cover OREX’s short positions. The SI to Orexigen Therapeutics Inc’s float is 7.56%. The stock increased 1.90% or $0.0039 during the last trading session, reaching $0.2089. About 747,996 shares traded. Orexigen Therapeutics, Inc. (NASDAQ:OREX) has declined 95.40% since March 30, 2017 and is downtrending. It has underperformed by 106.95% the S&P500.

Among 5 analysts covering Orexigen Therapeutics (NASDAQ:OREX), 2 have Buy rating, 2 Sell and 1 Hold. Therefore 40% are positive. Orexigen Therapeutics had 13 analyst reports since August 5, 2015 according to SRatingsIntel. As per Tuesday, March 13, the company rating was downgraded by Wells Fargo. Piper Jaffray maintained Orexigen Therapeutics, Inc. (NASDAQ:OREX) rating on Saturday, August 8. Piper Jaffray has “Buy” rating and $21 target. The rating was reinitiated by Bank of America on Friday, December 11 with “Underperform”. The firm has “Sell” rating given on Wednesday, August 5 by Zacks. The stock of Orexigen Therapeutics, Inc. (NASDAQ:OREX) earned “Overweight” rating by Piper Jaffray on Tuesday, October 6. The firm earned “Outperform” rating on Friday, November 6 by RBC Capital Markets. JP Morgan maintained Orexigen Therapeutics, Inc. (NASDAQ:OREX) on Monday, August 10 with “Buy” rating. The firm has “Market Perform” rating by Wells Fargo given on Friday, December 4. RBC Capital Markets upgraded the shares of OREX in report on Tuesday, September 15 to “” rating. The company was downgraded on Wednesday, March 16 by JMP Securities.

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. The company has market cap of $3.95 million. It offers Contrave for the treatment of obesity. It currently has negative earnings. The firm also offers Contrave under the Mysimba brand name.

Moon Capital Management Llc increased Berkshire Hathaway (BRKB) stake by 8,700 shares to 50,737 valued at $10.06B in 2017Q4. It also upped Microsoft (NASDAQ:MSFT) stake by 4 shares and now owns 3,817 shares. Exxon Mobil Corp. (NYSE:XOM) was raised too.

Among 9 analysts covering Brookfield Asset Management Inc. (NYSE:BAM), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Brookfield Asset Management Inc. had 32 analyst reports since August 10, 2015 according to SRatingsIntel. The firm has “Sector Outperform” rating given on Friday, October 16 by IBC. The firm has “Buy” rating given on Monday, October 2 by Canaccord Genuity. The firm has “Buy” rating given on Tuesday, March 27 by Scotia Capital. TD Securities maintained Brookfield Asset Management Inc. (NYSE:BAM) rating on Thursday, November 9. TD Securities has “Buy” rating and $52.0 target. The firm has “Buy” rating given on Thursday, January 19 by Citigroup. RBC Capital Markets maintained Brookfield Asset Management Inc. (NYSE:BAM) rating on Friday, February 16. RBC Capital Markets has “Buy” rating and $46.0 target. RBC Capital Markets maintained the stock with “Buy” rating in Tuesday, July 25 report. The stock of Brookfield Asset Management Inc. (NYSE:BAM) earned “Top Pick” rating by RBC Capital Markets on Monday, November 14. Wood initiated Brookfield Asset Management Inc. (NYSE:BAM) rating on Tuesday, May 24. Wood has “Outperform” rating and $41 target. The stock of Brookfield Asset Management Inc. (NYSE:BAM) earned “Buy” rating by Keefe Bruyette & Woods on Friday, November 10.

Brookfield Asset Management Inc. (NYSE:BAM) Ratings Chart